Shares of Catalyst Biosciences, Inc. (NASDAQ:CBIO) have received an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus price target of $10.50 for the company, according to Zacks. Zacks has also assigned Catalyst Biosciences an industry rank of 114 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research upgraded shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a report on Wednesday, November 8th.

Shares of Catalyst Biosciences (CBIO) opened at $4.72 on Wednesday. Catalyst Biosciences has a 52 week low of $3.11 and a 52 week high of $21.30.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu KCG Holdings LLC bought a new position in Catalyst Biosciences in the 2nd quarter worth $103,000. Bank of New York Mellon Corp bought a new position in shares of Catalyst Biosciences during the 2nd quarter worth about $107,000. Zacks Investment Management bought a new position in shares of Catalyst Biosciences during the 2nd quarter worth about $147,000. Vanguard Group Inc. increased its holdings in shares of Catalyst Biosciences by 294.1% during the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 32,621 shares during the period. Finally, Dimensional Fund Advisors LP bought a new position in shares of Catalyst Biosciences during the 2nd quarter worth about $372,000. Hedge funds and other institutional investors own 29.17% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/catalyst-biosciences-inc-cbio-receives-average-rating-of-strong-buy-from-brokerages/1703699.html.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Catalyst Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.